The New England journal of medicine
-
Editorial Comment
Global HIV Treatment - Turning Headwinds to Tailwinds.
-
Randomized Controlled Trial Multicenter Study
Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.
Establishing cardiovascular safety of new therapies for type 2 diabetes is important. Safety data are available for the subcutaneous form of the glucagon-like peptide-1 receptor agonist semaglutide but are needed for oral semaglutide. ⋯ In this trial involving patients with type 2 diabetes, the cardiovascular risk profile of oral semaglutide was not inferior to that of placebo. (Funded by Novo Nordisk; PIONEER 6 ClinicalTrials.gov number, NCT02692716.).